|
| Vol. 9.32 – 20 August, 2020
|
|
|
|
|
|
|
|
KTN1-AS1 knockdown inhibited cell growth and proliferation, increased apoptosis, and modulated the expression of cell cycle- and apoptosis-related proteins in non-small cell lung cancer cell lines and tumor xenografts in nude mice.
[Oncogene]
|
|
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers identified a toxic mechanism and the potential health effects of ambient dust in an underground subway station. At 24 hour exposure to human bronchial epithelial cells, dust located within autophagosome-like vacuoles, whereas a series of autophagic processes appeared to be blocked.
[Environmental Research]
|
|
|
|
|
|
Scientists found that EGCG treatment blocked cigarette smoke extract-induced oxidative stress as indicated by decreased production and accumulation of reactive oxygen species in airway epithelial cells.
[Life Sciences]
|
|
|
|
|
|
The authors investigated the beneficial effects of rutin-loaded liquid crystalline nanoparticles against lipopolysaccharide induced oxidative damage in human bronchial epithelial cells in vitro.
[Toxicology in Vitro]
|
|
|
|
|
|
Investigators determined whether the exposure to a relatively low dose of well‐characterized iron‐rich nanoparticles might alter some critical toxicological endpoints in a relevant primary culture model of human bronchial epithelial cells.
[Journal of Applied Toxicology]
|
|
|
|
|
|
|
|
Researchers identified LINC00467 as the up-regulated lncRNA that was common significantly differentially expressed in non-small cell lung cancer and CRC tissues from the GEO database.
[Oncogene]
|
|
|
|
|
|
Anti-metastatic activities of peptide fibrillar assemblies were demonstrated by in vitro inhibition of lung cancer cell migration and clonogenesis.
[Biomacromolecules]
|
|
|
|
|
|
Investigators examined whether apelin enhanced proliferation and invasion ability of lung cancer cells via exosomal miRNA.
[Carcinogenesis]
|
|
|
|
|
|
PD-L1-chimeric antigen receptor (CAR) T cells exhibited antigen-specific activation, cytokine production, and cytotoxic activity against PD-L1high non-small cell lung carcinoma cells and xenograft tumors.
[Oncogenesis]
|
|
|
|
|
|
Researchers showed, using next-generation sequencing, that SOX2 expressed in the ASCL1-high small cell lung cancer subtype cell line was dependent on ASCL1, which is a lineage-specific transcriptional factor, and was involved in neuroendocrine differentiation and tumorigenesis.
[Laboratory Investigation]
|
|
|
|
|
|
The authors investigated correlations between PD-L1+ cancer stem cells, changes in T-cell phenotype in metastatic and non-metastatic lymph nodes and response to treatment.
[Cancer Immunology Immunotherapy]
|
|
|
|
|
|
Scientists studied TTA-A2 and paclitaxel in lung adenocarcinoma cell line- A549, cancer cells and human embryonic kidney cell line- HEK 293, control cell, in their monolayer and spheroids forms for viability, proliferation, morphology change, migration, and invasion-after 48–96 hours of treatment.
[Life Sciences]
|
|
|
|
|
|
Researchers evaluated the inhibitory effect of a tyrosine kinase inhibitor sunitinib and the integrin-αⅤβ3 targeted cyclic peptide (cRGDfK) on EMT in human lung cancer cells.
[PLoS One]
|
|
|
|
|
|
|
|
The authors discuss recent developments in T2R biology and their role in cellular physiology and expand on the therapeutic potential of T2R agonists in treatment of asthma.
[Current Opinion in Pharmacology]
|
|
|
|
|
|
|
|
Verona Pharma plc announced the initiation of the second, multiple dose, part of a Phase II trial to evaluate the pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe chronic obstructive pulmonary disease.
[Verona Pharma plc]
|
|
|
|
|
|
Enterprise Therapeutics Ltd announced it has successfully dosed the first subjects in a Phase I trial for its novel inhaled cystic fibrosis therapy, ETD002.
[Enterprise Therapeutics Ltd]
|
|
|
|
|
|
Vasomune Therapeutics announced it has received a Peer-Reviewed Medical Research Program grant award effective August 1, 2020 for US $2.8 million from the US Department of Defense for the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome.
[Vasomune Therapeutics]
|
|
|
|
|
|
|
|
July 8 – July 10, 2021
Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
| Institut Mondor de Recherche Biomédicale (IMRB) – Creteil, France
|
|
|
|
|
|
| University of British Columbia – Vancouver, British Columbia, Canada
|
|
|
|
|
|
| Institute for Computational Medicine – Baltimore, Maryland, United States
|
|
|
|
|
|
| Columbia University Medical Center – New York, New York, United States
|
|
|
|
|
|
| Fred Hutchinson Cancer Research Center – Seattle, Washington, United States
|
|
|
|
|
|